BioCardia's CardiAMP non-significantly improves 6MWD in roll-in cohort of Phase III for heart failure

BioCardia Inc. (OTCQX:BCDA) reported data from the 10-patient roll-in cohort of the Phase III CardiAMP Heart Failure trial to treat heart failure following a heart attack showing that CardiAMP non-significantly improved mean 6-minute walk distance (6MWD) at 12 months by 46.4 meters compared with baseline (p=0.063). Data were presented at the American Heart Association (AHA) meeting in Chicago...